Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Exchange Rate Effect (2020 - 2025)

Apellis Pharmaceuticals has reported Exchange Rate Effect over the past 6 years, most recently at $184000.0 for Q4 2025.

  • Quarterly results put Exchange Rate Effect at $184000.0 for Q4 2025, up 119.07% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 289.68% YoY), and the annual figure for FY2025 was $1.2 million, up 289.68%.
  • Exchange Rate Effect for Q4 2025 was $184000.0 at Apellis Pharmaceuticals, up from $22000.0 in the prior quarter.
  • Over the last five years, Exchange Rate Effect for APLS hit a ceiling of $685000.0 in Q2 2025 and a floor of -$1.6 million in Q1 2021.
  • Median Exchange Rate Effect over the past 5 years was $15000.0 (2021), compared with a mean of -$88900.0.
  • Biggest five-year swings in Exchange Rate Effect: tumbled 959.87% in 2021 and later soared 2237.5% in 2022.
  • Apellis Pharmaceuticals' Exchange Rate Effect stood at $8000.0 in 2021, then soared by 2237.5% to $187000.0 in 2022, then soared by 212.3% to $584000.0 in 2023, then crashed by 265.24% to -$965000.0 in 2024, then skyrocketed by 119.07% to $184000.0 in 2025.
  • The last three reported values for Exchange Rate Effect were $184000.0 (Q4 2025), $22000.0 (Q3 2025), and $685000.0 (Q2 2025) per Business Quant data.